Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,504 active trials253 approved drugs3,568 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,622 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03393117 | Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Breast Recontruction | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Jul 22, 2020 | clinicaltrials |
| NCT04439305 | Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 20, 2020 | clinicaltrials |
| NCT02547948 | CD19-targeting CAR T Cells for B Cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT02547961 | Chimeric Antigen Receptor-Modified T Cells for Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT02575261 | CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients | withdrawn | Phase 1 / Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT03252171 | CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients | withdrawn | Phase 1 / Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT04406610 | CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients | withdrawn | Phase 1 / Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 0 | Jul 16, 2020 | clinicaltrials |
| NCT04272645 | Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 15, 2020 | clinicaltrials |
| NCT03003728 | 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT) | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 1 | Jul 10, 2020 | clinicaltrials |
| NCT04013880 | ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Jul 7, 2020 | clinicaltrials |
| NCT03617484 | Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma | withdrawn | Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 22, 2020 | clinicaltrials |
| NCT00753740 | Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients. | withdrawn | Phase 2 | 0 | NewLink Genetics CorporationINDUSTRY | 1 | Jun 12, 2020 | clinicaltrials |
| NCT04149444 | A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer(TACTIC) | withdrawn | Phase 2 | 0 | AHS Cancer Control AlbertaOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT02831491 | A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Eli Lilly and CompanyINDUSTRY | 0 | Jun 9, 2020 | clinicaltrials |
| NCT04184518 | Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma(CEDUVEAL-M) | withdrawn | Phase 2 | 0 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT02923986 | Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS | withdrawn | Phase 1 / Phase 2 | 0 | Bio-Path Holdings, Inc.INDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT03517995 | Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention | withdrawn | Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT04016116 | Dual PD-1 and JAK2 Inhibition in Hematological Malignancies | withdrawn | Phase 2 | 0 | NYU Langone HealthOTHER | 1 | May 27, 2020 | clinicaltrials |
| NCT03801499 | Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 21, 2020 | clinicaltrials |
| NCT03104335 | Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial | withdrawn | Phase 2 | 0 | Peking University People's HospitalOTHER | 1 | May 19, 2020 | clinicaltrials |
| NCT00367718 | Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma | withdrawn | Phase 2 | 0 | Johns Hopkins UniversityOTHER | 2 | May 18, 2020 | clinicaltrials |
| NCT03065712 | Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT03927248 | PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer | withdrawn | Phase 1 / Phase 2 | 0 | HealthPartners InstituteOTHER | 0 | May 7, 2020 | clinicaltrials |
| NCT03637868 | Eribulin in Brain Metastases From HER2-negative Breast Cancer(ERIBRAIN) | withdrawn | Phase 2 | 0 | Institut Paoli-CalmettesOTHER | 1 | May 6, 2020 | clinicaltrials |
| NCT01355562 | Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer | withdrawn | Phase 2 | 0 | Loma Linda UniversityOTHER | 1 | Apr 30, 2020 | clinicaltrials |
| NCT03400254 | Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")(GLACIER) | withdrawn | Phase 1 / Phase 2 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 28, 2020 | clinicaltrials |
| NCT03719560 | Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma(BrUOG-377) | withdrawn | Phase 2 | 0 | Brown UniversityOTHER | 1 | Apr 13, 2020 | clinicaltrials |
| NCT03768531 | Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 0 | Apr 13, 2020 | clinicaltrials |
| NCT01019278 | Proton Beam Radiation Therapy and Cisplatin in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer and Positive Lymph Nodes | withdrawn | Phase 2 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Apr 3, 2020 | clinicaltrials |
| NCT04100330 | A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia(CyFi2) | withdrawn | Phase 2 | 0 | AVEO Pharmaceuticals, Inc.INDUSTRY | 0 | Mar 31, 2020 | clinicaltrials |
| NCT03739801 | MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | withdrawn | Phase 1 / Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Mar 27, 2020 | clinicaltrials |
| NCT04024384 | Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial(DARALLO) | withdrawn | Phase 2 | 0 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 27, 2020 | clinicaltrials |
| NCT03986086 | MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation | withdrawn | Phase 1 / Phase 2 | 0 | Nelson ChaoOTHER | 1 | Mar 20, 2020 | clinicaltrials |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Zhi YangOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT03688230 | Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.(AMELION) | withdrawn | Phase 2 | 0 | SFJ Pharmaceuticals X, LTD.INDUSTRY | 0 | Mar 18, 2020 | clinicaltrials |
| NCT04025567 | Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Mar 16, 2020 | clinicaltrials |
| NCT04058964 | Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 13, 2020 | clinicaltrials |
| NCT03678090 | The Safety and Efficacy of Fibrinolysis in Patients With an Indwelling Pleural Catheter for Multi-loculated Malignant Pleural Effusion. | withdrawn | Phase 2 | 0 | Yale UniversityOTHER | 0 | Mar 5, 2020 | clinicaltrials |
| NCT02487849 | HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma(HIPEC) | withdrawn | Phase 2 | 0 | Krankenhaus Barmherzige Schwestern LinzOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT02811809 | Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer | withdrawn | Phase 2 | 0 | The University of Texas Health Science Center, HoustonOTHER | 1 | Feb 27, 2020 | clinicaltrials |
| NCT03328936 | Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant | withdrawn | Phase 2 | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 21, 2020 | clinicaltrials |
| NCT02580253 | Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT03973879 | Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma | withdrawn | Phase 1 / Phase 2 | 0 | Darell BignerOTHER | 0 | Feb 11, 2020 | clinicaltrials |
| NCT03146039 | Non-Invasive Cervical Cancer Radiotherapy for Stage IB-IVB(NICER) | withdrawn | Phase 2 | 0 | University of California, San DiegoOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03818997 | Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer(DYNAMIC) | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Feb 5, 2020 | clinicaltrials |
| NCT04134468 | MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma | withdrawn | Phase 2 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT03323424 | Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers(IRAM) | withdrawn | Phase 2 | 0 | Institut de Cancérologie de la LoireOTHER | 1 | Jan 30, 2020 | clinicaltrials |
| NCT03579927 | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 29, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Jul 22, 2020source: clinicaltrials